Heba Jalil

Jan 11, 2025 | cellandgene.com | Jackie Mulryne |Eftychia Sideri |Heba Jalil |Antony Hitchcock

With over 450 unique products in clinical development and 50 anticipated approvals by 2030, the evolving regulatory landscape for cell and gene therapies is more critical than ever. Don't miss your chance to gain expert insights! Join the next Cell & Gene Live for an exclusive digital panel discussion exploring forward-looking perspectives on this transformative field. Registration is free—thanks to the support of Thermo Fisher Scientific.

Dec 4, 2024 | cellandgene.com | Jackie Mulryne |Eftychia Sideri |Heba Jalil |Rich Buonaiuto Tree

On-Demand Webinar: Expanding CAR T Beyond OncologyCAR T therapies, known for bringing groundbreaking treatment advancements to oncology, are beginning to show promise in additional therapeutic areas. Watch our on-demand webinar to explore how collaboration between therapeutically aligned teams impacts study delivery for CAR T in autoimmune disease and neurology clinics.

Dec 1, 2024 | mondaq.com | Jackie Mulryne |Eftychia Sideri |Heba Jalil

On October 21, 2024, the Medicines and Healthcare products Regulatory Agency (MHRA) announced that the U.K. will be the first country in the world to introduce a tailored framework for the manufacture of innovative medicines at or close to the location where a patient receives care.

Nov 14, 2024 | bioprocessonline.com | Jackie Mulryne |Eftychia Sideri |Heba Jalil

By Jackie Mulryne, Eftychia Sideri, and Heba Jalil, Arnold & Porter On October 21, 2024, the Medicines and Healthcare products Regulatory Agency (MHRA) announced that the U.K. will be the first country in the world to introduce a tailored framework for the manufacturer of innovative medicines at or close to the location where a patient receives care.

Sep 29, 2023 | lexblog.com | Jackie Mulryne |Eleri Williams |Heba Jalil

On 19 September 2023, the UK Government launched the pilot phase of the Innovative Devices Access Pathway (IDAP), an initiative to help bring innovative technologies to the NHS where there is an unmet medical need. As discussed in a previous post, IDAP has been designed to accelerate the development of innovative medical devices, with the aim of taking delays and uncertainty out of the route to market.